Trials / Completed
CompletedNCT03696069
A Study is to Understand the Treatment Patterns for Immunotherapy Agents and BRAF/MEK Inhibitors Used in the Treatment of Advanced Melanoma
Understanding the Treatment Patterns, Healthcare Resource Utilization, Costs of Care, and Clinical Outcomes Among Patients Treated for Advanced Melanoma
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 501 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of the study is to understand the treatment patterns for immunotherapy agents and BRAF/MEK inhibitors used in the treatment of advanced melanoma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Non-Interventional | Non-Interventional |
Timeline
- Start date
- 2019-01-09
- Primary completion
- 2019-12-27
- Completion
- 2020-02-14
- First posted
- 2018-10-04
- Last updated
- 2022-02-10
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT03696069. Inclusion in this directory is not an endorsement.